Kashima N, Nakajima H, Katsura T, Sugihara S, Fukaura A, Takahashi T
First Department of Internal Medicine, Showa University School of Medicine.
Arerugi. 1993 Jun;42(6):723-7.
We examined serum PLA2, lipids and platelets in 133 bronchial asthma patients who had not taken any glucocorticoids. Serum PLA2 was measured by radioimmunoassay. Serum PLA2 activity in the bronchial asthma patients was 384.2 +/- 114.7 (pmol/ml/min), and in the control group (healthy subjects) it was 271.7 +/- 53.9; this is a statistically significant difference (p < 0.01). Serum PLA2 of the mixed type was higher than that of the atopic type (p < 0.05) with respect to age, those subjects in their 60s showed statistically higher serum PLA2 values than those in their 20s and 30s (p < 0.05). The serum PLA2 level was statistically higher in a patient with an attack (409.1 +/- 113.9) than without an attack (342.6 +/- 94.3) (p < 0.05). However, there was no significant difference in lipid and platelet levels according to attack status. In conclusion, the serum PLA2 level is not only higher in asthma patients with attacks, but is also higher in asthma patients without attacks when compared to the control group. Therefore, the measurement of serum PLA2 is significant in predicting attacks.
我们检测了133例未服用任何糖皮质激素的支气管哮喘患者的血清磷脂酶A2（PLA2）、血脂和血小板。血清PLA2采用放射免疫分析法测定。支气管哮喘患者的血清PLA2活性为384.2±114.7（pmol/ml/分钟），而对照组（健康受试者）为271.7±53.9；这是一个具有统计学意义的差异（p<0.01）。就年龄而言，混合型血清PLA2高于特应型（p<0.05），60多岁的受试者血清PLA2值在统计学上高于20多岁和30多岁的受试者（p<0.05）。发作患者的血清PLA2水平（409.1±113.9）在统计学上高于未发作患者（342.6±94.3）（p<0.05）。然而，根据发作状态，血脂和血小板水平没有显著差异。总之，血清PLA2水平不仅在发作的哮喘患者中较高，而且与对照组相比，在未发作的哮喘患者中也较高。因此，血清PLA2的检测对预测发作具有重要意义。
